Drug Combo Proves Effective for Pattern Hair Loss in Women

This article originally appeared here.
Share this content:
Drug Combo Proves Effective for Pattern Hair Loss in Women
Drug Combo Proves Effective for Pattern Hair Loss in Women

WEDNESDAY, Dec. 20, 2017 (HealthDay News) -- Once-daily capsules containing a combination of minoxidil and spironolactone appear to be safe and effective for the treatment of female pattern hair loss (PHL), according to a case-series study published online Dec. 12 in the International Journal of Dermatology.

Rodney D. Sinclair, M.B.B.S., M.D., from Epworth Hospital in East Melbourne, Australia, presents a case series of 100 women with PHL treated with once-daily minoxidil 0.25 mg and spironolactone 25 mg. Shedding and hair density were scored before and after 12 months of treatment.

Sinclair observed a 0.85 mean reduction in hair loss severity score at six months and a 1.3 mean reduction at 12 months. There was also a mean reduction of 2.3 in hair shedding score at six months and a mean reduction of 2.6 at 12 months. There was a drop in blood pressure observed among participants (mean change, −4.52 mm Hg systolic and −6.48 mm Hg diastolic). Eight women experienced side effects, which were generally mild, although two who developed urticaria discontinued treatment. No cases of hyperkalemia or any other blood test abnormality were reported.

"Most women noticed a reduction in hair shedding at three months and an increase in hair density at six months," Sinclair writes. "Placebo-controlled studies to investigate this further are warranted."

Sinclair discloses holding a related innovation patent.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »